Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
63
resultados
Última actualización
20/03/2026 [07:36:00]
Resumen de: AU2024341403A1
The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of disease (e.g., lymphoma).
Resumen de: AU2024328882A1
There is provided A compound of formula I, a salt or solvate thereof as described herein, for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative disorders, colorectal cancer, medulloblastoma, renal, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous cancer, gastrointestinal stromal tumor, glioma, myxofibrosarcoma, leiomyosarcoma, neuroblastoma, synovial sarcoma, mesothelioma, gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer, and neural cancer.
Resumen de: AU2024321283A1
Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and/or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.
Resumen de: EP4711444A2
The present invention provides compositions and methods for the mitigation of side effects of chemotherapy, for example in human subjects with hematologic malignancies (such as lymphoma, leukemia and myelodysplastic syndrome) as well as subjects with other malignancies or other conditions that may be treated with chemotherapy, such as high dose therapy (HDT) or a combination of high dose HDT and a hematopoietic stem cell transplant. The methods comprise administration of endothelial cells, such as engineered human umbilical vein endothelial cells engineered to express the adenoviral E4ORF1 protein (E4ORF1+ HUVECs), to human subjects. The side effects mitigated by the compositions and methods of the invention include, but are not limited to, oral / gastrointestinal side effects and febrile neutropenia.
Resumen de: EP4710937A1
Problem The purpose is to provide a novel pharmaceutical composition that can be used to induce an immune response to HTLV-1. Solution The pharmaceutical composition of the present disclosure comprises: human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein p15 (Gag p15) or an immunogenic fragment thereof, Gag protein p19 (Gag p19) or an immunogenic fragment thereof, and/or Gag protein p24 (Gag p24) or an immunogenic fragment thereof; and a pharmaceutically acceptable carrier
Resumen de: EP4711463A1
Problem A composition and a method that can be used to induce an immune response to HTLV-1 are required.Solution A lipid complex comprising at least one nucleic acid selected from: a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein; a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic Tax protein; and a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic HBZ protein; wherein the at least one nucleic acid is encapsulated in a lipid.
Resumen de: EP4711382A1
Use of a micropeptide MIAC, which belongs to the technical field of biomedicine. The present disclosure specifically relates to use of the micropeptide MIAC in preparation of a reagent or a medicament for detecting, preventing or treating tumors. The tumors comprise one or more of solid tumors and hematologic malignancies, such as pancreatic cancer, hepatocellular carcinoma, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancies, myeloma, cholangiocarcinoma and prostate cancer. The micropeptide MIAC has the effects of inhibiting growth, proliferation and/or migration of various tumor cells, has a wide treatment spectrum, and is suitable for diagnosing, preventing or treating various tumors, specifically malignant tumors.
Resumen de: EP4711456A1
The present invention relates to a method for the manufacture of individualized CRISPR/Cas complexes comprising the steps a) identifying in a tumor specimen of a human cancer patient a mutation at position 38.141.150 on chromosome 3, and b) preparing for the mutation identified in a) an individualized CRISPR/Cas complex, wherein the individualized CRISPR/Cas complex comprises a guide RNA and a Cas endonuclease, wherein the CRISPR/Cas complex targets the mutation; a method, preferably an in-vitro method, for inducing cell death or impairment of cell proliferation in cancerous or pre-cancerous cells of B-cell-lymphocytes; a composition related thereto and individualized CRISPR/Cas complexes preferably for use in the treatment of B-cell-lymphoma or for inducing cell death or impairment of cell proliferation in cancerous or pre-cancerous B-cell-lymphocytes.
Resumen de: US20260069584A1
The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolerable at a dose from 10 mg to 210 mg.
Resumen de: WO2026054717A1
Disclosed herein are methods of enhancing the abundance of NKG2C+ adaptive NK cells in a population of NK cells and the use of NK cells expressing NKG2C derived from such methods for treatment of cancers, including leukemia such as chronic myeloid leukemia with enhanced expression of HLA-E molecule. In one embodiment, the method is a biphasic method comprising a selection phase and an expansion phase. In one embodiment, the selection phase comprises use of a first culture comprising IL-2 and feeder cells expressing HLA-E. In one embodiment, the expansion phase comprises use of a second culture comprising IL-2, IL-15 and feeder cells expressing HLA-E, IL-21 and 4-1 BBL. Also disclosed are methods of stratifying chronic myeloid leukemia patients into responders or non-responders to tyrosine kinase inhibitor to allow a suitable treatment for each group with tyrosine kinase inhibitor or NK cells expressing NKG2C derived from the described methods. In one embodiment, the stratification method comprises determining a percentage of NKG2A+ cells in the patients' NK cell population.
Resumen de: US20260070946A1
The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.
Resumen de: US20260070935A1
Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.
Resumen de: US20260071196A1
The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.
Resumen de: AU2024317966A1
The present disclosure provides antigen-binding proteins specifically binding GPRC5D, as well as respective antibodies in enhanced ADCC formats, and methods of using them to treat cancers such as multiple myeloma.
Resumen de: US20260070998A1
The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that bind to BCMA and CD3) in combination with a CD38 inhibitor (e.g., an anti-CD38 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.
Resumen de: WO2026055333A1
The invention provides methods for treating and selecting cancer patients for therapy using a compound that modulates mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) activity, such as inhibiting MALT1 scaffolding activity.
Resumen de: WO2026055492A1
Disclosed herein are methods of administering a Casitas B-lineage lymphoma proto-oncogene B inhibitor (CBL-Bi) for treating a cancer in a subject. Additionally disclosed herein are methods of administering a pre-treatment in combination with the CBL-Bi for treating a cancer in a subject.
Resumen de: US20260069625A1
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.
Resumen de: US20260069567A1
The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.
Resumen de: WO2026055154A1
The present disclosure provides methods and kits for obtaining sequence information of one or more genes from a subject diagnosed with a disease or disorder. Based on the sequence information, the present disclosure further provides methods of predicting a treatment outcome of the subject.
Resumen de: WO2026055403A1
Provided are compounds of the Formula PTM-L-CLM, or a pharmaceutically acceptable salt thereof, wherein the PTM is (PTM-I) These compounds are useful for the degradation of BCL6 and in the treatment cancer.
Resumen de: WO2026055296A2
Methods of producing Minute Mouse Virus (MMV) stock are described herein. Methods of producing xenotropic murine leukemia virus (xMuLV) stock are described herein.
Resumen de: EP4706673A2
The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.
Resumen de: US20260049279A1
The invention features polypeptides and/or transgenic effector cells including T cell receptors (TCRs) which specifically bind anaplastic lymphoma kinase (ALK) antigens or peptide sequences, and the use of such polypeptides and/or transgenic effector cells and TCRs specific to anaplastic lymphoma kinase (ALK) antigens or peptide sequences in compositions and methods for treating ALK-positive neoplasias such as Non-Small Cell Lung Cancers (NSCLCs).
Nº publicación: EP4706682A2 11/03/2026
Solicitante:
PENN STATE RES FOUND [US]
The Penn State Research Foundation
Resumen de: EP4706682A2
A pharmaceutical composition, comprising the compound NSC350625, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in a method of treating CNS cancer, lung cancer or lymphoma in a subject.
BOPI
Sede Electrónica
